du Buf-Vereijken Peggy W G, Wetzels Jack F M
Department of Internal Medicine, Amphia Hospital, Molengracht, PO Box 90158, 4800 RK Breda, The Netherlands.
Nephrol Dial Transplant. 2006 Feb;21(2):389-96. doi: 10.1093/ndt/gfi219. Epub 2005 Oct 18.
In patients with idiopathic membranous nephropathy, an increased urinary excretion of high (IgG) and low [beta(2)-microglobulin (beta(2)M), alpha(1)-microglobulin (alpha(1)M)] molecular weight proteins predicts prognosis and precedes renal insufficiency. We have studied the changes in the urinary excretion of these proteins in patients with idiopathic membranous nephropathy and renal insufficiency during and after treatment with cyclophosphamide and steroids, and investigated their value in predicting long-term outcome.
Standardized measurements of urinary IgG, albumin, beta(2)M and alpha(1)M were performed at 0, 2, 6 and 12 months in 11 patients, at 12 months in 25 patients and in 17 of these last patients after 2-5 years.
We observed a rapid improvement of glomerular permselectivity and tubular protein reabsorption within 2 months after the start of therapy. Despite a partial remission of proteinuria within 12 months in most patients, evidence of tubulo-interstitial injury remained apparent. Neither absolute levels of urinary IgG, beta(2)M or alpha(1)M at baseline or at 12 months nor the percentage reduction between baseline and 12 months clearly predicted the occurrence of a remission or a relapse to nephrotic range proteinuria. In the case of a persistent stable remission, we observed a gradual decrease of urinary beta(2)M towards normal values.
In patients with idiopathic membranous nephropathy and renal insufficiency, treatment with cyclophosphamide and steroids resulted in an improvement of glomerular permeability and tubular proteinuria. Tubular proteinuria remained present for many years, even in patients with stable remission of proteinuria. Measurements of urinary proteins at 12 months after treatment start lacked predictive accuracy.
在特发性膜性肾病患者中,高分子量(IgG)和低分子量[β2微球蛋白(β2M)、α1微球蛋白(α1M)]蛋白质的尿排泄增加可预测预后,并先于肾功能不全出现。我们研究了特发性膜性肾病合并肾功能不全患者在环磷酰胺和类固醇治疗期间及治疗后的这些蛋白质尿排泄变化,并探讨了它们在预测长期预后方面的价值。
对11例患者在0、2、6和12个月时进行尿IgG、白蛋白、β2M和α1M的标准化测量,对25例患者在12个月时进行测量,并对其中17例患者在2至5年后进行测量。
我们观察到治疗开始后2个月内肾小球滤过选择性和肾小管蛋白重吸收迅速改善。尽管大多数患者在12个月内蛋白尿部分缓解,但肾小管间质损伤的证据仍然明显。基线或12个月时尿IgG、β2M或α1M的绝对水平,以及基线至12个月之间的降低百分比,均不能明确预测缓解的发生或肾病范围蛋白尿的复发。在持续稳定缓解的情况下,我们观察到尿β2M逐渐降至正常水平。
在特发性膜性肾病合并肾功能不全的患者中,环磷酰胺和类固醇治疗可改善肾小球通透性和肾小管蛋白尿。即使蛋白尿稳定缓解的患者,肾小管蛋白尿也会持续多年。治疗开始后12个月时的尿蛋白测量缺乏预测准确性。